This trial investigated activity of praziquantel and commiphora molmol (mirazid) combination regimen in the treatment of urinary Schistosomiasis infected patients. The sample population was composed of 845 individuals (400 school children and 445 adult). Screening for Schistosoma haematobium was done using microscopical examination of urine samples either directly or after centrifugation. Three samples were examined for each case. All positive eligible subjects were randomly assigned into four groups, the first received mirazid at a dose of 600 mg/day (two capsules before breakfast) for three consecutive days, the second received praziquantel at a single dose of 40 mg/kg and the third received combination of praziquantel at a single dose of 40 mg/kg followed by mirazid at a dose of 600 mg/day (two capsules before breakfast) for three consecutive days. Fourth group used as a control group. AII treated subjects were examined three days, one, two, and four weeks post-treatment. Mirazid showed low cure rates of 45 and 50 % for school children and household members, respectively, 73.6 and 81.8%, respectively, in those treated with praziquantel compared with 100% cure rate in both school children and household members with the combination regimen. Therefore, we recommend this combination as an agent to control Schistosomiasis.